The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group XY is NHSO.sub.2 or SO.sub.2NH; Z is a monocyclic aryl or heteroaryl group, each of which is optionally substituted by one or more substituents selected from alkyl, cycloalkyl, halo, alkoxy, CN, haloalkyl and OH; R.sub.1 is H or alkyl; R.sub.2 is selected from COOH and a tetrazolyl group; R.sub.3 is selected from H, C land alkyl; R.sub.4 is selected from H and halo; R.sub.5 is selected from H, alkyl, haloalkyl, SO.sub.2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R.sub.6 is H; R.sub.7 is selected from H, CN, haloalkyl, halo, SO.sub.2-alkyl, SO.sub.2NR.sub.12R.sub.13, heteroaryl, CONR.sub.10R.sub.11 and alkyl, wherein said heteroaryl group is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R.sub.8 is selected from H, alkyl, haloalkyl and halo; and R.sub.9 is H, alkyl or halo; R.sub.10 and R.sub.11 are each independently H or alkyl; and R.sub.12 and R.sub.13 are each independently H or alkyl. Further aspects of the invention relate to such compounds for use in the field of immuno-oncology and related applications. Another aspect of the invention relates to compounds of formulae (1a) and (1b). ##STR00001##

Provided is a compound of Chemical Formula 1: ##STR00001##
wherein, in Chemical Formula 1: X.sub.1 to X.sub.3 are each independently N or CH, provided that at least one of X.sub.1 to X.sub.3 is N; X.sub.4 to X.sub.6 are each independently N or CH, provided that at least one of X.sub.4 to X.sub.6 is N; Ar.sub.1 to Ar.sub.4 are each independently a substituted or unsubstituted C.sub.6-60 aryl, or a substituted or unsubstituted C.sub.2-60 heteroaryl containing any one or more selected from the group consisting of N, O, and S; L.sub.1 to L.sub.3 are each independently a single bond, a substituted or unsubstituted C.sub.6-60 arylene, or a substituted or unsubstituted C.sub.2-60 heteroarylene containing any one or more selected from the group consisting of N, O, and S; and n is 1 or 2, and an organic light emitting device including the same.

Provided is a compound of Chemical Formula 1: ##STR00001##
wherein, in Chemical Formula 1: X.sub.1 to X.sub.3 are each independently N or CH, provided that at least one of X.sub.1 to X.sub.3 is N; X.sub.4 to X.sub.6 are each independently N or CH, provided that at least one of X.sub.4 to X.sub.6 is N; Ar.sub.1 to Ar.sub.4 are each independently a substituted or unsubstituted C.sub.6-60 aryl, or a substituted or unsubstituted C.sub.2-60 heteroaryl containing any one or more selected from the group consisting of N, O, and S; L.sub.1 to L.sub.3 are each independently a single bond, a substituted or unsubstituted C.sub.6-60 arylene, or a substituted or unsubstituted C.sub.2-60 heteroarylene containing any one or more selected from the group consisting of N, O, and S; and n is 1 or 2, and an organic light emitting device including the same.

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Disclosed herein are nanoactuating rotaxanes comprising a threading component, the threading component comprising a oligoviologen, and at least two macrocylic components, wherein the oligoviologen is threaded through each of the macrocylic components. Also disclosed are methods for making and using the rotaxanes.

Disclosed herein are nanoactuating rotaxanes comprising a threading component, the threading component comprising a oligoviologen, and at least two macrocylic components, wherein the oligoviologen is threaded through each of the macrocylic components. Also disclosed are methods for making and using the rotaxanes.

This invention relates to compounds that are agonists of the muscarinic M.sub.1 receptor or M.sub.1 and M.sub.4 receptors and which are useful in the treatment of muscarinic M.sub.1 or M.sub.1/M.sub.4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula ##STR00001##
wherein Q.sup.4, Q.sup.5, R.sup.5, p, V, Q.sup.1, Q.sup.2, X.sup.1, X.sup.2 and W are defined herein.

This invention relates to compounds that are agonists of the muscarinic M.sub.1 receptor or M.sub.1 and M.sub.4 receptors and which are useful in the treatment of muscarinic M.sub.1 or M.sub.1/M.sub.4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula ##STR00001##
wherein Q.sup.4, Q.sup.5, R.sup.5, p, V, Q.sup.1, Q.sup.2, X.sup.1, X.sup.2 and W are defined herein.

The invention relates to the use of a compound of formula (I)

##STR00001##

or a salt thereof for combating animal pests,
where the symbols and indices are defined in the specification.